ストックスクリーナーアプリを入手
11.47
0.97%
0.11
アフターアワーズ：
11.42
-0.05
-0.44%
前日終値:
$11.36
開ける：
$11.45
24時間の取引高:
300.95K
Relative Volume:
0.41
時価総額：
$413.13M
収益：
$10.00M
当期純損益:
$-75.99M
株価収益率:
-4.8046
EPS:
-2.3873
ネットキャッシュフロー:
$-80.36M
1週間 パフォーマンス:
-0.52%
1か月 パフォーマンス:
-54.45%
6か月 パフォーマンス:
-41.48%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.21
$12.01
1週間の範囲:
$10.47
$12.37
52週間の値動き範囲:
$10.47
$33.20
Evommune Inc Stock (EVMN) Company Profile
Compare EVMN vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
11.47 | 409.17M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | 再開されました | Oppenheimer | Outperform |
| 2026-01-22 | 開始されました | Oppenheimer | Outperform |
| 2026-01-08 | 開始されました | Raymond James | Strong Buy |
| 2026-01-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 開始されました | Evercore ISI | Outperform |
| 2025-12-01 | 開始されました | Leerink Partners | Outperform |
| 2025-12-01 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-01 | 開始されました | William Blair | Outperform |
すべてを表示
Evommune Inc (EVMN) 最新ニュース
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EVMN|Evommune Inc|Price:11.360|Chg%:+0.060 - TradingKey
Evommune Inc (EVMN) Cash Flow - TradingKey
TradingKey - TradingKey
Evommune Inc (EVMN) Balance Sheet - TradingKey
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc (EVMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evommune (EVMN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Top Evommune (EVMN) Competitors 2026 - MarketBeat
Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD - TradingView
Evommune Inc. Q1 2026 Earnings: EPS Beat Exceeds Expectations Amid Pre-Revenue PhaseSurprise Factor Analysis - dars.gov.et
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Clear Street Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
If You Invested $1,000 in EVOMMUNE INC (EVMN) - Stock Titan
Kyle Carver Increases Stake in Evommune Inc with Recent Share Pu - GuruFocus
Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock - MarketBeat
Independent Director of Evommune Arthur Kirsch Buys More Stock - simplywall.st
Form 4 Evommune Inc For: 8 July By Investing.com - Investing.com South Africa
Evommune director Arthur Kirsch buys $133,000 of EVMN stock By Investing.com - Investing.com India
Evommune (NYSE:EVMN) Director Acquires $133,000.00 in Stock - MarketBeat
Evommune director Arthur Kirsch buys $133,000 of EVMN stock - Investing.com
Evommune, Inc. (EVMN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Evommune Inc. (EVMN) Rises 3.4%: Testing Key Resistance LevelsSymmetrical Triangle - dars.gov.et
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
EVMNEvommune Inc Options - Finviz
Evommune, Inc. (NYSE: EVMN) Stock Price, News & Analysis - Kalkine
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market - TipRanks
Evommune’s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN) - Seeking Alpha
Evommune drops on phase 2 data for EVO756 in urticaria - MSN
Evommune's EVO756 trial miss raises doubts but pipeline and finances remain strong. - Pluang
Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development - The Dermatology Digest
Evommune shares plunge 38% after lead drug fails Phase 2b trial; insiders sold shares days before news. - Pluang
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - Morningstar
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - The Globe and Mail
Evommune stock downgraded by H.C. Wainwright after trial failure - Investing.com South Africa
EVMN Maintained by Morgan Stanley -- Price Target Lowered to $26 - GuruFocus
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Evommune Inc : RBC Cuts Target Price to $30 F - Moomoo
A Quick Look at Today's Ratings for Evommune(EVMN.US), With a Forecast Between $26 to $28 - Moomoo
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes - BioSpace
EVMN Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Evommune Inc (EVMN) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):